Skip to content

Pluristyx

2 viewers · 30d

Total raised

$9.8M

+$9.8M this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $9.8M
ROUNDS
1
INVESTORS
13
FOUNDED
N/A
HQ
Seattle, WA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
2

AI overview

Updated

Pluristyx is a Seattle-based biotechnology company supplying induced pluripotent stem cell (iPSC) products and manufacturing services for cell and gene therapy developers. It sells research- and clinical-grade iPSC lines and banks, culture and cryopreservation kits, differentiated cells, and custom cell lines, and provides gene editing, process development, and GMP manufacturing. Its proprietary engineering technologies include the FailSafe safety switch and iACT Stealth Cells immune-evasion package for allogeneic therapies. The company operates sites in Seattle, Washington and Toronto, Canada.

What sets it apart

Combines off-the-shelf clinical-grade iPSC banks with proprietary gene-editing technologies (FailSafe safety switch, iACT Stealth immune cloaking), which the company says lets clients reach GMP edited iPSC banks in about 18 months with a large reduction in development timelines.

Funding history

1 round
EquityJul 1, 2026
Form D
+$9.8M$9.8M total

Latest SEC filings

via EDGAR · CIK 0001991664
Form D · Jul 1, 2026NewView on EDGAR

Products

1 tracked

Pluristyx iPSC platform

Cell therapy raw materials and contract development

An integrated platform of ready-to-use and custom induced pluripotent stem cell products backed by gene editing and GMP manufacturing, spanning PluriBank iPSC banks, PluriKit and PluriFreeze culture and cryopreservation products, custom iPSC lines, and differentiated cells.

  • Research-grade and clinical/GMP-grade iPSC cell banks (PluriBank)
  • FailSafe safety switch for engineered cell products
  • iACT Stealth Cells immune-evasion engineering for allogeneic therapies
  • Custom iPSC line generation and differentiation services

Links

WebsiteLinkedInSEC EDGAR filings